These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 8599821)
1. [What do we know about the significance of vitamin D in Paget's disease of the bone?]. Wilczek H; Stĕpán J; Justová V Cas Lek Cesk; 1995 Dec; 134(24):785-7. PubMed ID: 8599821 [TBL] [Abstract][Full Text] [Related]
2. Vitamin D in Paget's disease of bone. Foldes J; Shamir S; Kidroni G; Menczel J Clin Orthop Relat Res; 1989 Jun; (243):275-9. PubMed ID: 2498022 [TBL] [Abstract][Full Text] [Related]
3. Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate. Devlin RD; Gutteridge DH; Prince RL; Retallack RW; Worth GK J Bone Miner Res; 1990 Nov; 5(11):1121-6. PubMed ID: 2125401 [TBL] [Abstract][Full Text] [Related]
4. [The correlation between the serum levels of osteocalcin and 24,25-dihydroxyvitamin D in Paget's disease of bone]. Castro Errecarborde N; de la Piedra Gordo C; Rapado Errazti A An Med Interna; 1990 Jun; 7(6):286-90. PubMed ID: 2102732 [TBL] [Abstract][Full Text] [Related]
5. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis. Torres R; de la Piedra C; Rapado A Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049 [TBL] [Abstract][Full Text] [Related]
6. [Monitoring plasma levels of vitamin D metabolites in simvastatin (Zocor) therapy in patients with familial hypercholesterolemia]. Wilczek H; Sobra J; Ceska R; Justová V; Jůzová Z; Procházková R; Kvasilová M Cas Lek Cesk; 1994 Dec; 133(23):727-9. PubMed ID: 7834670 [TBL] [Abstract][Full Text] [Related]
7. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468 [TBL] [Abstract][Full Text] [Related]
8. Abnormal vitamin D metabolism in Paget's disease of bone. Guillard-Cumming DF; Beard DJ; Douglas DL; Johnson SK; Lawson-Matthew PJ; Russell RG; Kanis JA Clin Endocrinol (Oxf); 1985 Apr; 22(4):559-66. PubMed ID: 3872746 [TBL] [Abstract][Full Text] [Related]
9. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment. Papapoulos SE; Frolich M; Mudde AH; Harinck HI; vd Berg H; Bijvoet OL J Clin Endocrinol Metab; 1987 Jul; 65(1):89-94. PubMed ID: 3495547 [TBL] [Abstract][Full Text] [Related]
10. [The value of the calcitonin test in Paget's disease of bone]. D'Amore M; Bozzi A; Telesca ML; Carrozzo M Minerva Med; 1981 Apr; 72(14):865-8. PubMed ID: 7219796 [TBL] [Abstract][Full Text] [Related]
11. [Is beta 2-microglobulin a marker of bone remodeling in Paget's disease of bone?]. Wilczek H Cas Lek Cesk; 1997 Dec; 136(23):730-2. PubMed ID: 9476376 [TBL] [Abstract][Full Text] [Related]
12. [Decrease of the coefficient of intestinal calcium absorption with normal blood levels of 1,25-dihydroxyvitamin D and decreasing levels of 24,25-dihydroxyvitamin D in Paget's disease of bone]. Traba ML; Climent P; Rapado A; de la Piedra C; Díaz Curiel M Rev Clin Esp; 1986 Nov; 179(8):401-3. PubMed ID: 3494277 [No Abstract] [Full Text] [Related]
13. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation. Mangham DC; Davie MW; Grimer RJ Bone; 2009 Mar; 44(3):431-6. PubMed ID: 19064007 [TBL] [Abstract][Full Text] [Related]
14. [Importance of vitamin D in prostatic carcinoma]. Wilczek H; Vachalovský Cas Lek Cesk; 1996 Nov; 135(22):716-8. PubMed ID: 8998822 [TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor, oestrogen receptor-alpha and calcium-sensing receptor genotypes, bone mineral density and biochemical markers in Paget's disease of bone. Donáth J; Speer G; Poór G; Gergely P; Tabák A; Lakatos P Rheumatology (Oxford); 2004 Jun; 43(6):692-5. PubMed ID: 14997007 [TBL] [Abstract][Full Text] [Related]
17. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate. Constantin A; Laroche M; Moulinier L; Bon E; Ramonjisoa M; Cantagrel A; Mazieres B Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612 [TBL] [Abstract][Full Text] [Related]
18. [Paget's disease of the bones: diagnosis and treatment]. Jacobs JW; Huisman AM; van Paassen HC; Bijlsma JW Ned Tijdschr Geneeskd; 1999 Apr; 143(14):719-25. PubMed ID: 10347626 [TBL] [Abstract][Full Text] [Related]
19. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094 [TBL] [Abstract][Full Text] [Related]
20. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone. Chakravarty K; Merry P; Scott DG J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]